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Neisseria cinerea Expresses a Functional
Factor H Binding Protein Which Is
Recognized by Immune Responses
Elicited by Meningococcal Vaccines
Hayley Lavender, Katy Poncin,* Christoph M. Tang
Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom
ABSTRACT Neisseria meningitidis is a major cause of bacterial meningitis and sepsis
worldwide. Capsular polysaccharide vaccines are available against meningococcal sero-
groups A, C, W, and Y. More recently two protein-based vaccines, Bexsero and Tru-
menba, against meningococcal serogroup B strains have been licensed; both vaccines
contain meningococcal factor H binding protein (fHbp). fHbp is a surface-exposed lipo-
protein that binds the negative complement regulator complement factor H (CFH),
thereby inhibiting the alternative pathway of complement activation. Recent analysis of
available genomes has indicated that some commensal Neisseria species also contain
genes that potentially encode fHbp, although the functions of these genes and how im-
munization with fHbp-containing vaccines could affect the commensal flora have yet to
be established. Here, we show that the commensal species Neisseria cinerea expresses
functional fHbp on its surface and that it is responsible for recruitment of CFH by the
bacterium. N. cinerea fHbp binds CFH with affinity similar to that of meningococcal fHbp
and promotes survival of N. cinerea in human serum. We examined the potential impact
of fHbp-containing vaccines on N. cinerea. We found that immunization with Bexsero
elicits serum bactericidal activity against N. cinerea, which is primarily directed against
fHbp. The shared function of fHbp in N. cinerea and N. meningitidis and cross-reactive re-
sponses elicited by Bexsero suggest that the introduction of fHbp-containing vaccines
has the potential to affect carriage of N. cinerea and other commensal species.
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The genus Neisseria includes two major human pathogens, Neisseria meningitidis andNeisseria gonorrhoeae (1, 2). N. meningitidis is a commensal of the human naso-
pharynx in approximately 10 to 40% of the general population but can traverse the
epithelial layer and cause systemic disease (3), while the gonococcus is a leading cause
of sexually transmitted disease (4). In contrast, nonpathogenic Neisseria species are
ubiquitous commensals of the human oral cavity and nasopharynx in healthy individ-
uals and constitute approximately 10% of the human oral bacterial flora (1, 5, 6). Even
though Neisseria polysaccharea, Neisseria lactamica, and Neisseria cinerea are closely
related to the meningococcus and the gonococcus (7, 8), there are only rare case
reports of invasive disease caused by these commensal species, and they are usually
limited to immunocompromised hosts (9).
N. meningitidis can be categorized into 13 serogroups based on the structure of its
polysaccharide capsule, with 6 serogroups (A, B, C, W, X, and Y) responsible for the
majority of disease worldwide (3, 10–13). Capsular polysaccharide conjugate vaccines
have been developed to protect individuals against disease caused by some sero-
groups of N. meningitidis (i.e., A, C, W, and Y), while outer membrane vesicle (OMV)
vaccines have been successfully employed to combat epidemic disease caused by
single strains (14, 15). However, these approaches cannot prevent endemic serogroup
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B N. meningitidis disease, which is still a significant cause of morbidity and mortality in
Europe and the United States (3). This is because immunization with the serogroup B
capsule, which is identical to a modification on NCAM-1 (16), can induce autoimmunity,
while OMV vaccines offer only limited cross protection against diverse strains (17–20).
Two recently licensed serogroup B vaccines, Bexsero and Trumemba, contain factor
H binding protein (fHbp) as a key antigen (21–23). fHbp is a 27-kDa surface lipoprotein
that is expressed by almost all disease-causing isolates of N. meningitidis (24, 25). The
protein elicits serum bactericidal activity (SBA), an accepted correlate of protection
against meningococcal disease (21, 22, 24). fHbp can be classified into one of three
variant groups (V1, V2, or V3) or two subfamilies (A and B) based on its amino acid
sequence (22, 26). Immunization with fHbp generally induces cross protection against
strains expressing an fHbp within the same variant group, with limited cross protective
immunity between variant groups (21).
fHbp promotes survival of N. meningitidis in serum by binding the negative com-
plement regulator complement factor H (CFH) at high affinity (25). CFH consists of 20
complement control protein (CCP) domains joined by short linker sequences, with each
domain consisting of approximately 60 amino acids (27–29). CFH inhibits the alterna-
tive pathway (AP) of complement by acting as a cofactor for factor I-mediated cleavage
of C3b, a key molecule in the complement cascade, and by accelerating the decay of
the AP C3 convertase (30–32). These functions are mediated by the first four CCP
domains (CFH1– 4), while other CCP domains have distinct functions, such as binding to
heparin and glycosaminoglycans (33, 34). N. meningitidis fHbp binds CCP domains 6
and 7 of CFH (CFH6 –7) (25, 35), while a further complement protein, CFHR3, also binds
to fHbp and acts as a competitive antagonist of CFH (36).
Recent genome analysis of 80 pathogenic and commensal Neisseria strains identified
fhbp in all N. meningitidis strains examined and homologues of fhbp in some commen-
sal species (37). A homologue of fhbp was also present in isolates of N. gonorrhoeae,
although the protein encoded by this gene, Ghfp, does not bind CFH to any significant
degree (38, 39). fhbp was also found in all isolates of N. cinerea and N. polysaccharea
examined (37–39). Of note, N. cinerea fhbp genes have significant nucleotide identity
with V1 fhbp, whereas N. gonorrhoeae and N. polysaccharea harbor homologues of V3
fhbp (37, 39).
Several lines of evidence indicate that commensal Neisseria spp. can induce immu-
nity against N. meningitidis. For example, colonization with N. lactamica during early
childhood is associated with the development of adaptive immunity against the
meningococcus (5, 40, 41). Moreover, individuals colonized with N. lactamica following
live challenge develop cross-reactive salivary IgA and serum IgG antibodies and appear
to be protected against subsequent acquisition of N. meningitidis (42). Therefore, the
presence of antigens, such as fHbp, in commensal Neisseria spp. raises the possibility
that implementation of protein-based vaccines containing fHbp could impact the
colonization of commensal species in the upper airway.
Here, we investigated whether fhbp in the N. cinerea genome encodes a functional
protein and examined its roles in binding CFH and complement evasion. We found that
N. cinerea expresses fHbp on its surface, where it binds CFH at high affinity and
mediates resistance against complement-mediated lysis. Furthermore, we evaluated
whether immune responses elicited by Bexsero have significant activity against N.
cinerea. We demonstrate that immune responses elicited by Bexsero have SBA against
N. cinerea, with fHbp the main target of SBA responses elicited by Bexsero against N.
cinerea, indicating that introduction of fHbp-containing vaccines could affect carriage
of commensal Neisseria spp.
RESULTS
N. cinerea fHbp is predicted to be structurally similar to meningococcal fHbp.
The genome sequences of five N. cinerea isolates, CCUG 346T, CCUG 5746, CCUG 25879,
CCUG 27178A, and CCUG 53043, from the PubMLST Neisseria BIGSdb database (http://
pubmlst.org/neisseria/) were interrogated for the presence of fhbp. Previously anno-
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tated fhbp sequences were verified by BLAST using the V1.1 fhbp nucleotide sequence
as the search query. All the isolates contain fhbp with a predicted signal peptide, a
conserved lipobox, and a variable linker sequence (see Fig. S1 in the supplemental
material), with a high degree of nucleotide sequence identity (95%) with V1.1 fhbp
from N. meningitidis, consistent with previous findings (37). Furthermore, N. cinerea
CCUG 346T fhbp is identical to the meningococcal fhbp peptide variant V1.110 (http://
pubmlst.org/neisseria/). We further characterized fhbp from N. cinerea using CCUG
346T, as the strain has previously been shown to be genetically tractable (43). The
predicted amino acid sequence of fHbp from N. cinerea CCUG 346T has six amino acid
differences from V1.1 fHbp (Fig. 1A). A structural model of N. cinerea fHbp was
generated using V1.1 fHbp as the threading template (25; Protein Data Bank [PDB]
accession no. 2W80) (Fig. 1B). One different amino acid, A58, is predicted to reside in
the leader peptide, while three of the residues unique to N. cinerea fHbp (H243, H269,
and D282) are in the C-terminal barrel of fHbp, distant from the CFH-fHbp interface (44).
Residues R193 and E267 in N. cinerea fHbp reside at the CFH-fHbp interface in close
proximity (i.e., within 4 Å) to S366 and N338 of CFH, respectively, which could potentially
lead to the formation of additional salt bridges between fHbp and CFH. Alanine substitution
for Q193 in meningococcal V1.1 fHbp leads to a 2-fold decrease in CFH binding compared
to wild-type V1.1 fHbp, while alanine substitution at position 267 in V2.21 fHbp (E267)
showed significantly reduced CFH binding, with no binding of CFH6–7 detected (44).
FIG 1 N. cinerea fHbp is predicted to be structurally similar to V1.1 fHbp. (A) Sequence alignment of N. meningitidis
V1.1 fhbp and N. cinerea V1.110 fhbp. The blue residues show sequence differences. (B) Predicted structure of N.
cinerea V1.110 fHbp (gray ribbon) generated with the I-TASSER server and V1.1 fHbp (blue ribbon [25]; PDB
accession no. 2W80). The figure was drawn using Pymol. Residues in red (shown as ball-and-stick representations)
are different in N. cinerea fHbp and V1.1 fHbp. Residues R193 and E267 (red) are in close proximity to the CFH
(green ribbon) binding site.
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N. cinerea fHbp binds CFH at high affinity. As amino acids in N. cinerea and N.
meningitidis fHbp proteins differ at the CFH interface, we next evaluated whether N.
cinerea fHbp binds CFH (37). N. cinerea fHbp was expressed as a recombinant protein
and purified as previously described (44). The protein was recognized by anti-V1.1 fHbp
serum by Western blot analysis, as expected (Fig. 2A). Initially, binding of fHbp from N.
cinerea and V1.1 fHbp from N. meningitidis to CFH was determined by far-Western
analysis using normal human serum (NHS) as the source of CFH. V1.1I311A fHbp was
used a negative control, as it has significantly impaired binding to CFH (44). The results
of far-Western analysis demonstrated that N. cinerea fHbp and wild-type V1.1 fHbp bind
CFH, while V1.1I311A fHbp has no detectable CFH binding, as previously described (44)
(Fig. 2A).
To further characterize this interaction, we determined the affinity of N. cinerea fHbp
for CFH6 –7 by surface plasmon resonance (SPR). N. cinerea fHbp binds to CFH6 –7 with
an affinity similar to that of V1.1 fHbp, with equilibrium binding constants (KDs) of 3.5 
0.5 nM and 3.0  0.5 nM, respectively (Fig. 2B and C), indicating that the amino acid
substitutions in N. cinerea V1.110 fHbp do not affect its ability to bind CFH. We also
FIG 2 N. cinerea V1.110 fHbp binds CFH at high affinity. (A) Recombinant V1.110 fHbp from N. cinerea (N c) CCUG 346T,
with V1.1 fHbp, and V1.1I311A fHbp from N. meningitidis (N m) were recognized by Western blotting using polyclonal
anti-V1.1 fHbp sera. N. cinerea V1.110 fHbp and V1.1 fHbp bound CFH by far-Western analysis with NHS as the source of
CFH. Molecular masses are shown, and Coomassie blue staining of proteins is shown as the loading control. (B) SPR analysis
of N. cinerea fHbp binding to recombinant CFH6 –7 (concentrations are indicated) with 1:1 Langmuir fit (black lines). (C)
Calculated KD values for CFH6 –7 binding to N. cinerea V1.110 fHbp and V1.1 fHbp; NBD, no binding detected. (D) ELISA of
N. cinerea fHbp, V1.1 fHbp, and V1.1I311A fHbp binding to full-length CFH. (E) Significance of CFH binding by ELISA analyzed
at 5 g/ml of CFH. The error bars indicate the standard error of the mean (SEM) from three independent experiments, and
P values (***, P  0.001; ns, P  0.05) were calculated using a two-tailed unpaired t test.
Lavender et al. Infection and Immunity
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determined the levels of CFH binding to N. cinerea fHbp and V1.1 fHbp by enzyme-
linked immunosorbent assay (ELISA) using full-length CFH (Fig. 2D and E). The ELISA
data were consistent with results from both far-Western and SPR analyses, with no
significant difference in CFH binding to N. cinerea fHbp and V1.1 fHbp over a range of
concentrations (P  0.05 by two-tailed t test) (Fig. 2E). Taken together, these results
demonstrate that N. cinerea fHbp binds CFH and that this interaction is mediated by
CFH6 –7 of CFH.
N. cinerea isolates express fHbp on the bacterial surface. Next, the expression of
fHbp by other N. cinerea isolates was analyzed using polyclonal mouse serum raised
against V1.1 fHbp, which cross-reacts with N. cinerea fHbp from CCUG 346T (Fig. 2A). A
band of approximately 27 kDa corresponding to the molecular mass of fHbp was
detected in lysates of all five N. cinerea isolates by Western blotting (Fig. 3A). Moreover,
five N. cinerea isolates were analyzed for the ability to bind full-length CFH present in
NHS; N. meningitidis H44/76 and H44/76Δfhbp were used as positive and negative
controls, respectively. Far-Western analysis detected a band corresponding to fHbp in
whole-cell lysates of N. cinerea isolates and the positive control, H44/76; no CFH binding
to N. meningitidis H44/76Δfhbp was detected, as previously described (39) (Fig. 3A). We
also sought to establish whether CFH binding to N. cinerea is dependent on fHbp.
FIG 3 Functional fHbp was expressed by all N. cinerea strains examined. (A) Western blot analysis of fHbp
expression using anti-V1.1 fHbp sera against N. cinerea strains and N. meningitidis H44/76 and H44/76Δfhbp.
Far-Western analysis demonstrated that fHbps from different N. cinerea isolates bound CFH. RecA was used
as a loading control. (B) Western and far-Western analyses demonstrating that binding of CFH to N. cinerea
is dependent on fHbp expression. (C) Temperature-dependent regulation of fHbp expression by N. cinerea,
examined by Western blot analysis using anti-V1.1 fHbp sera. RecA, loading control, with relative fHbp
expression levels (rel. values) shown.
Neisseria cinerea fHbp Infection and Immunity
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Therefore, we constructed an fhbp mutant of N. cinerea CCUG 346T by insertional
inactivation of the gene with a kanamycin resistance cassette. Analysis of the wild-type
N. cinerea and the Δfhbp strain demonstrated that the Δfhbp mutant did not express
fHbp, as expected, while far-Western blot analysis demonstrated that CFH binding to N.
cinerea is dependent on fHbp (Fig. 3B).
Our previous work demonstrated that N. meningitidis fHbp is subject to thermal
regulation, with higher levels of fHbp produced by strains grown at higher tempera-
tures (i.e., 37°C and 42°C compared with 30°C) (45, 46). Therefore, we investigated
whether N. cinerea fHbp is also thermoregulated. N. cinerea CCUG 346T was harvested
following growth of the bacteria in brain heart infusion (BHI) broth to mid-log phase at
30°C, 37°C, or 42°C; the relative fHbp expression levels were quantified by Western blot
analysis (Fig. 3C). The results demonstrated that increasing temperature is associated
with elevated fHbp expression in N. cinerea, similar to the meningococcus (P  0.0382;
one-way analysis of variance [ANOVA] for 30°C versus 42°C) (Fig. 3C). Inspection of
sequences corresponding to the 5= untranslated region (UTR) of fhbp from N. cinerea
CCUG 346T indicated that there is a single base change (C-U) in the fumarate-nitrate
reduction regulator (FNR) box, but the temperature-regulatory domains identified in N.
meningitidis MC58 (46) are conserved in N. cinerea CCUG 346T (see Fig. S2 in the
supplemental material). Two putative -ribosome binding sites (-RBS) in the open
reading frame (ORF) of fHbp of N. meningitidis MC58 have been shown to determine
temperature regulation of fHbp (46), and N. cinerea CCUG 346T retains an identical
sequence for -RBS1 (CUGCCU) (see Fig. S2 in the supplemental material) but has a C-U
substitution in the second -RBS.
To analyze surface expression of fHbp in N. cinerea, we performed flow cytometry
analysis using anti-V1.1 fHbp serum to detect fHbp on the surfaces of N. cinerea CCUG
346T and CCUG 346TΔfhbp (Fig. 4A and B); N. meningitidis H44/76 and H44/76Δfhbp
were included as positive and negative controls, respectively (Fig. 4C and D). The results
demonstrated that fHbp is detected on the surface of N. cinerea CCUG 346T, as well as
N. meningitidis H44/76; fHbp was not detected on either of the fhbp mutants (two-tailed
t test; P  0.0001 and P  0.0183 compared with the respective wild-type strains).
N. cinerea fHbp promotes complement resistance. Next, we investigated whether
fHbp can recruit CFH to the surface of N. cinerea. N. cinerea CCUG 346T and CCUG
346TΔfhbp were incubated in heat-inactivated (HI) NHS as a source of CFH, and CFH
was detected by flow cytometry with an -CFH monoclonal antibody (MAb), OX24 (Fig.
5A and B) (47); binding was quantified as the geometric mean fluorescence intensity.
Bacteria incubated in phosphate-buffered saline (PBS) or in CFH-depleted serum (HI-
CFH depleted) were used as controls. Following incubation with HI-NHS, CFH was
detected on the surface of N. cinerea (Fig. 5A and B), while no CFH binding was found
either after incubating wild-type bacteria with HI-CFH-depleted serum or PBS or after
incubating the fhbp mutant in HI-NHS (two-tailed t test; P  0.0002) (Fig. 5A to D),
demonstrating that CFH binds to the surface of N. cinerea in an fHbp-dependent
manner.
Next, we examined the functional consequences of CFH binding to N. cinerea by
performing serum survival assays. N. cinerea CCUG 346T and CCUG 346TΔfhbp were
incubated in NHS (concentrations ranging from 0 to 20%) for 30 min, and the
percent survival was calculated by comparing the number of CFU recovered after
incubation in serum with the number of CFU recovered after incubation in PBS. N.
cinerea CCUG 346T was significantly more resistant to complement-mediated lysis
than CCUG 346TΔfhbp over a range of serum concentrations (Fig. 6A). For example,
there was 54% and 31% survival for CCUG 346T and CCUG 346TΔfhbp, respectively,
in 5% NHS (two-tailed t test; P  0.0161). Furthermore, we examined whether these
differences in survival were observed in the presence of only the AP of complement
by inhibiting the activities of the classical and lectin pathways by the addition of 10
mM EGTA and 5 mM MgCl2 to sera (48). N. cinerea CCUG 346T still demonstrated a
trend toward enhanced serum resistance compared to CCUG 346TΔfhbp when only
Lavender et al. Infection and Immunity
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the AP was active in a 15% serum concentration, although this did not reach
statistical significance (two-tailed t test; P  0.127) (52.28% and 38.94% survival for
CCUG 346T and CCUG 346TΔfhbp, respectively) (Fig. 6B). Furthermore, we analyzed
whether an N. meningitidis fhbp mutant, H44/76Δfhbp, could be complemented
with N. cinerea fHbp (V1.110). N. meningitidis H44/76, H44/76Δfhbp, and H44/
76Δfhbp complemented with either meningococcal V1.1 fHbp or N. cinerea fHbp
were incubated in NHS (concentrations ranging from 0 to 75%) for 30 min, and the
percent survival was calculated. Both complemented strains, H44/76Δfhbp::V1.1fhbp
and H44/76Δfhbp::V1.110fhbp, were significantly more resistant to NHS than H44/
76Δfhbp (one-way ANOVA; P  0.0023 and P  0.0046, respectively), and no
significant difference in survival was observed between the complemented strains
and H44/76 at 75% NHS (Fig. 6C). Taken together, these results demonstrate that N.
cinerea fHbp contributes to the evasion of killing by the complement system.
fHbp-containing vaccines elicit SBA against N. cinerea. Finally we examined
whether the licensed meningococcal vaccine, Bexsero, which contains meningococcal
fHbp, elicits immune responses against N. cinerea. Mice were immunized with Bexsero
or an equivalent amount (20 g) of V1.1 fHbp; sera from mice immunized with adjuvant
alone were used as a negative control. Initially, we used ELISA to measure the ability of
antibodies in pooled immune sera to recognize V1.1 fHbp and N. cinerea fHbp.
Interestingly, there was no significant difference in the recognition of V1.1 fHbp and N.
cinerea fHbp by antibodies in sera from mice immunized with Bexsero or V1.1 fHbp (Fig.
7A; data from mice immunized with fHbp V1.1 not shown) (P  0.05 by two-tailed t
test). Next, the reactivity of sera was examined by Western blotting of whole-cell lysates
FIG 4 N. cinerea fHbp is present on the bacterial surface. Flow cytometry analysis with anti-V1.1 fHbp serum
demonstrated detection of fHbp on the surfaces of N. cinerea (solid black line) (A and B) and N. meningitidis
(solid blue line) (C and D). The error bars indicate the standard error of the mean (SEM) from three
independent experiments. Significance was calculated using a two-tailed unpaired t test; ****, P  0.0001;
*, P  0.05.
Neisseria cinerea fHbp Infection and Immunity
October 2017 Volume 85 Issue 10 e00305-17 iai.asm.org 7







from N. cinerea CCUG 346T and N. meningitidis H44/76 (Fig. 7B). Sera from mice
immunized with V1.1 fHbp detected a band of the size expected for fHbp by Western
blot analysis of lysates of wild-type strains, while no protein was detected in the Δfhbp
mutants, as previously observed for polyclonal sera against V1.1 fHbp (see Fig. S3A in
the supplemental material) (44). As expected, sera from mice immunized with Bexsero
detected multiple protein bands in whole-cell lysates (see Fig. S3B) due to the complex
mixture of the vaccine (23), although a band corresponding to the molecular mass of
fHbp was detected in lysates of N. cinerea CCUG 346T, but not from the Δfhbp mutant.
Sera from mice immunized with either recombinant fHbp or Bexsero also recognized
recombinant V1.1 and N. cinerea V1.110 fHbp (Fig. 7B).
Next, the potential impact of immune responses raised against Bexsero on N.
cinerea was examined by measuring SBA. Immunization with V1.1 fHbp or Bexsero
elicited SBA titers of 128 against N. cinerea CCUG 346T; SBA titers of 8 are
correlated with protection against serogroup B meningococcal disease (Fig. 7C)
(49). Of note, sera from mice immunized with Bexsero had a higher SBA titer (256)
against N. cinerea CCUG 346T complemented with N. cinerea fHbp under an IPTG
(isopropyl--D-thiogalactopyranoside)-inducible promoter than wild-type bacteria,
consistent with higher expression of fHbp by the complemented strain (not shown).
Furthermore, no SBA was detected against N. cinerea CCUG 346TΔfhbp with either
V1.1 fHbp or Bexsero, demonstrating that SBA elicited by Bexsero against N. cinerea
FIG 5 Surface-bound CFH contributes to complement resistance of N. cinerea in an fHbp-dependent manner.
Shown is flow cytometry analysis of CFH binding to N. cinerea CCUG 346T (A and B) and N. cinerea CCUG 346TΔfhbp
(C and D). The shaded areas indicate results from bacteria incubated with PBS, the solid green lines show bacteria
incubated in HI-NHS, and the dashed green lines show bacteria incubated in HI-CFH-depleted sera. The data are
presented as the mean fluorescence intensity. The error bars indicate the standard error of the mean (SEM) from
three independent experiments, and the P values were calculated using a two-tailed unpaired t test; ***, P  0.001;
ns, P  0.05.
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is mediated by fHbp. In conclusion, immune responses elicited by Bexsero recog-
nize N. cinerea fHbp and have significant SBA.
DISCUSSION
fHbp is a key virulence factor for the meningococcus and binds the negative
complement regulator CFH, promoting bacterial survival in human serum (25, 50, 51).
The importance of fHbp as a vaccine antigen is evident from its inclusion in two
recently licensed serogroup B meningococcal vaccines (21, 22). Here, we show that
fHbp expression is not restricted to pathogenic N. meningitidis but that the antigen is
also expressed by the commensal species N. cinerea, in which fHbp is surface located
and binds CFH at high affinity. Recruitment of CFH by N. cinerea promotes its survival
FIG 6 N. cinerea fHbp contributes to complement resistance. (A and B) Sensitivity of N. cinerea and N.
cinerea CCUG 346TΔfhbp to complement-mediated lysis in the presence of NHS (A) and in the presence
of the AP of complement only (B). (C) Survival in human serum of N. meningitidis H44/76, H44/76Δfhbp,
and H44/76Δfhbp complemented with either V1.1 fHbp or N. cinerea V1.110 fHbp. The error bars indicate
the standard error of the mean (SEM) from three independent experiments.
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in human serum complement, while serum raised against Bexsero has SBA against N.
cinerea expressing fHbp.
Previous work has analyzed the expression and function of fHbp in pathogenic
Neisseria spp. (39, 50, 51). fHbp is a highly variable protein that can be grouped into
three distinct variants based on its amino acid sequence (26). Using SPR, we found that
N. cinerea fHbp binds CFH in the nanomolar range, similar to the affinity of CFH for V1.1
fHbp from N. meningitidis, indicating that high-affinity binding of CFH to the surface of
the bacterium is not only involved during survival in the bloodstream, but likely aids
colonization and persistence in the human nasopharynx. In contrast, N. gonorrhoeae,
which resides in the genitourinary tract, expresses a nonfunctional fHbp called Ghfp
(39) and instead recruits CFH via an abundant surface porin, PorB.1 (52, 53). A frameshift
mutation in the nucleotide sequence at position 40 of ghfp disrupts the lipobox,
resulting in the loss of surface localization of Ghfp (39), and sequence changes in ghfp
result in a protein that is unable to bind CFH (39). The distinct mechanisms by which
N. meningitidis and N. cinerea recruit CFH compared with N. gonorrhoeae are likely to
reflect differences in concentrations of CFH and the levels of other complement
proteins at the sites they occupy in the body. Complement proteins, including C3b, may
be derived from exudates on the nasopharyngeal mucosa from the subepithelial
microvasculature (54, 55). Levels of C3 in nasopharyngeal secretions are estimated to be
approximately 6.6% of serum C3 levels (range, 4.2 to 20.2%), indicating that there is a
significant level of complement in the nasopharynx (56). Although CFH could not be
detected on respiratory epithelial cells by immunohistochemistry (57), levels of the
complement regulator in saliva range from 0.007 to 0.059 g/ml (0.04 to 0.38 nM) (58,
59), which is significantly lower than in serum. There are few studies on CFH in the
genital tract, although low levels of CFH have been detected in urothelial cells, which
also can produce C3 (57). High-affinity interactions with CFH might be required at
mucosal surfaces due to low availability of this important complement regulator (58,
59). Furthermore, levels of CFH and other complement proteins may change during
FIG 7 Immunization with Bexsero elicits SBA against N. cinerea. (A) ELISA analysis of anti-Bexsero mouse
sera (3-fold dilutions from 1/300) against recombinant fHbp; BSA was used as a control. The error bars
indicate the standard error of the mean (SEM) from three independent experiments. (B) fHbp (27 kDa) is
recognized by sera from mice immunized with V1.1 fHbp or Bexsero as determined by Western blot
analysis. The higher-molecular-mass band observed when whole-cell extracts were probed with sera from
mice immunized with Bexsero was likely due to responses against other proteins in the vaccine. (C) Serum
bactericidal titers of pooled sera from mice immunized with recombinant V1.1 fHbp or Bexsero against N.
cinerea strains; NBT, no bactericidal titer.
Lavender et al. Infection and Immunity
October 2017 Volume 85 Issue 10 e00305-17 iai.asm.org 10







inflammation, when CFH recruitment might provide an advantage for commensal and
pathogenic bacteria in avoiding exudates of serum components and putatively could
aid N. cinerea colonization of the nasopharynx (56, 60, 61).
Binding of CFH is important for nasopharyngeal colonization by other bacteria,
including Streptococcus pneumoniae (62), by mediating interactions with respiratory
epithelial cells. Binding of CFH to PspC on the pneumococcus significantly increases its
attachment to human epithelial and endothelial cells by acting as a molecular bridge
between the bacteria and host cells (63). Moreover, the RGD motif in CCP4 of CFH can
recognize integrins on cells to induce uptake of the pneumococcus (63, 64). A similar
role for CFH acting as a molecular bridge has not been described for N. meningitidis or
N. cinerea as yet and merits further investigation, as similar mechanisms might influ-
ence N. meningitidis and N. cinerea colonization of the human nasopharynx.
Although N. cinerea expresses fhbp, other, closely related commensal species, such
as N. lactamica and N. polysaccharea, do not express fHbp. The majority of N. polysac-
charea isolates have a frameshift in the ORF, potentially producing a truncated protein,
while fhbp has not been identified in the N. lactamica genome, indicating that fHbp is
not essential for successful colonization of the human nasopharynx by Neisseria spp.
Previous work has suggested that NspA and PorB2 of N. meningitidis can bind CFH,
although these proteins have little effect in wild-type strains and specific binding affinities
are not known (65, 66). Although N. cinerea CCUG 346T carries a gene encoding PorB2, we
found no evidence by Western blotting or flow cytometric analysis that molecules other
than fHbp are responsible for N. cinerea binding to CFH. Of note, N. cinerea CCUG 346T is
not predicted to harbor a functional nspA gene. Other functional roles that could enhance
bacterial survival have also been attributed to meningococcal fHbp, including protecting
against the cationic antimicrobial peptide LL-37 (67). LL-37 is a cathelicidin that is expressed
by epithelial cells in the nasopharynx (68, 69). Furthermore, both fHbp and Ghfp have been
postulated to act as siderophore receptors and to recruit enterobactin and so could
contribute to iron scavenging on mucosal surfaces (70).
Previously, we demonstrated that meningococcal fHbp levels are elevated with
increasing temperatures, i.e., from 30°C to 37 and 42°C (45, 46). Thermoregulation of
meningococcal fHbp is mediated by two putative -RBS within the ORF of fhbp; at
lower temperatures, the transcript forms a stem-loop structure including the RBS, thus
reducing fHbp expression (46, 71). Sequence analysis of N. cinerea CCUG 346T indicated
that the 5= UTR upstream of fhbp, including the monocistronic promoter, is conserved
compared with N. meningitidis MC58 and includes the RBS and one repeat of the -RBS
within the fhbp ORF (see Fig. S2 in the supplemental material). The second -RBS has
a single residue change, C-U, although N. cinerea fHbp is still subject to temperature
regulation (Fig. 3C). Temperature is also an indicator of local inflammation, which could
expose the bacterium to host immune effectors. Therefore, upregulation of fHbp could
provide N. cinerea with a selective advantage over other commensal Neisseria spp. that
do not expresses the antigen (72, 73).
Conjugate vaccines against N. meningitidis have been highly successful at reducing
carriage of the pathogen but do not affect commensal Neisseria spp., as they target
specific capsular polysaccharides that are not expressed by commensal species (74, 75).
Limited data are currently available on the impact of Bexsero and other protein-based
vaccines on meningococcal carriage (76, 77). As IgG and complement are present on
mucosal surfaces (54, 78, 79), it is possible that immune responses against fHbp could
affect the nasopharyngeal carriage of bacteria expressing fHbp. We found that immu-
nization of mice with Bexsero elicited SBA against N. cinerea, with titers similar to those
found in mice immunized with fHbp alone. Furthermore, there was no SBA against N.
cinerea lacking fHbp, indicating that fHbp is largely responsible for the SBA seen with
Bexsero. With regard to other protein antigens found in Bexsero, genes encoding
GNA2091 and GNA1030 are present in all N. cinerea isolates, whereas only fragments of
nadA are found in some isolates (37). NHBA and PorA have not been identified in any
N. cinerea isolate analyzed to date. However, as N. cinerea lacks a capsule, it may be
more susceptible than N. meningitidis to immune responses elicited by Bexsero against
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surface proteins. Therefore, it will be important to evaluate the impact of Bexsero on
the carriage of commensal Neisseria, as carriage of nonpathogenic species can induce
cross protective immunity (5, 42, 80).
In summary, we have shown that N. cinerea expresses functional fHbp on its surface,
where it contributes to complement evasion. Moreover, Bexsero elicits bactericidal
antibodies against N. cinerea, with SBA responses similar to immunization with fHbp
alone. Therefore, implementation of vaccines containing fHbp has the potential to
affect the commensal nasopharyngeal flora, and the impact of multicomponent vac-
cines should be assessed in future challenge studies.
MATERIALS AND METHODS
Sequence analysis and model of N. cinerea fHbp. N. cinerea fhbp sequences were extracted from
previously annotated whole-genome sequences available in the PubMLST BIGSdb database (http://
pubmlst.org/neisseria/). Alignments of the predicted N. cinerea fHbp sequence against the V1.1 fHbp
were generated by Clustal OMEGA (http://www.ebi.ac.uk/Tools/msa/clustalo/); residues were numbered
according to V1.1 fhbp. A model of N. cinerea fHbp was generated using the iTASSER server (81) with V1.1
fHbp (25; PDB accession no. 2W80). The resulting model is illustrated in PyMol (https://www.pymol.org/)
and has high confidence, with a C score of 1.68.
Bacterial strains and growth. The strains used in this study are listed in Table 1. Neisseria species
were grown on BHI agar (1.5% [wt/vol]; Oxoid) supplemented with 5% defibrinated horse blood. Bacteria
grown on solid media were incubated overnight at 37°C in the presence of 5% CO2. Liquid cultures in
BHI broth were inoculated with 109 CFU per 10 ml and grown with shaking at 180 rpm at the specified
temperatures to an A600 of 0.5 unless otherwise indicated. Antibiotics were added to media at the
following concentrations: kanamycin, 100 g ml1, and erythromycin, 10 g ml1. Escherichia coli was
grown in Luria-Bertani (LB) broth or on LB agar. Overnight liquid cultures were grown at 37°C with
shaking at 180 rpm in 5 ml of medium inoculated from a single colony. The bacteria were diluted 1 in
100 the next morning into larger volumes for protein expression. Antibiotics were added at the following
concentrations for E. coli: kanamycin, 50 g ml1, and carbenicillin, 100 g ml1.
Generation of plasmids and protein purification. Genomic DNA was isolated using a Wizard
Genomic DNA purification kit (Promega) according to the manufacturer’s instructions. fhbp was amplified
from N. cinerea genomic DNA using primers Ffhbp (5=-GCCATATGATGGCCGCCGACAT-3=; NdeI site under-
lined) and Rfhbp (5=-GCCTCGAGTTGCTTGGCGGCAAGGCCGATAT-3=; XhoI site underlined). The product
was ligated into pET-21b (Table 2), resulting in a construct for expression of fHbp with a C-terminal His
tag under an inducible promoter. fHbp expression was performed as described previously (44).
In brief, for protein expression, E. coli BL21(D3) (Agilent) containing fHbp expression constructs was
grown in liquid medium to an A600 of 0.4 to 0.8; then, IPTG was added to a final concentration of 1 mM.
After 4 h, the bacteria were harvested by centrifugation at 5,000  g for 30 min at 4°C prior to cell lysis
in an EmulsiFlex-C5 homogenizer (Avestin) at 15,000 lb/in2. The lysates were centrifuged at 50,000  g
for 30 min at 4°C, and recombinant fHbp was purified by affinity chromatography using a HisTrap column
(GE Healthcare) and eluted with 200 mM imidazole. Further purification was performed with an AKTA
TABLE 1 N. cinerea and N. meningitidis strains used in this study
Strain fHbp variant Yr identified Reference
N. cinerea
CCUG 346T V1.110 Unknown 7
CCUG 346TΔfHbp This study
CCUG 346TΔfHbp::fhbp V1.110 This study
CCUG 25879 V1.564 1989 7
CCUG 27178 A V1.110 1983 7
CCUG 53043 V1.534 2006 85
CCUG 5746 V1.563 1977 7
N. meningitidis
H44/76 V1.1 1976 86
H44/76Δfhbp 39
H44/76Δfhbp::V1.1 fhbp V1.1 39
H44/76Δfhbp::V1.110 fhbp V1.110 This study
TABLE 2 E. coli BL21(DE3)Lys plasmids
Plasmid Insert Modification Source
pET21b V1.1 fhbp 44
pET21b V1.1 fhbp I311A 44
pET21b V1.110 fhbp This study
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purifier (GE Healthcare) by anion-exchange chromatography (HiTrapQ HP column; GE Healthcare).
Protein concentrations were estimated using a Nanodrop 2000c spectrophotometer (Thermo Scientific).
SDS-PAGE and Western blot analysis. Recombinant protein (10 g) and whole-cell extracts were
separated on 12% or 14% polyacrylamide gels prior to transfer to Immobilon P polyvinylidene difluoride
(PVDF) membranes (Millipore, USA) using the Trans-Blot SD semidry transfer system (Bio-Rad, USA) or
staining for 10 min with Coomassie blue. For whole-cell extracts, N. meningitidis and N. cinerea were
grown on solid medium overnight and resuspended in PBS. The number of bacteria was determined by
measuring the DNA concentration by the A260 of 20 l of the bacterial suspension in 980 l of lysis buffer
(0.1 M NaOH, 1% SDS); 109 CFU was mixed with an equal volume of 2 SDS-PAGE loading buffer (100
mM Tris-HCl, pH 6.8, 20 M -mercaptoethanol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and
boiled for 10 min. For Western blot analysis, membranes were blocked in 0.05% (wt/vol) dry milk-PBS
with 0.05% (vol/vol) Tween 20 overnight and then incubated with primary antibodies or with NHS as a
source of CFH. Primary antibodies were used at the following concentrations: anti-V1.1 fHbp polyclonal
sera, 1:1,000 (44); anti-RecA, 1:5,000 (Abcam, Cambridge); anti-CFH, 1:10,000 (Millipore). Horseradish
peroxidase (HRP)-conjugated secondary antibodies, goat anti-mouse HRP (Dako, United Kingdom), rabbit
anti-goat HRP (Dako, United Kingdom), and goat anti-rabbit HRP (Santa Cruz Biotechnology, Germany),
were used at a final concentration of 1:10,000. Membranes were washed three times in PBS with 0.05%
(vol/vol) Tween 20, and binding was detected using an ECL Western blotting detection kit (Amersham,
USA).
To examine the effect of temperature on fHbp expression, N. cinerea was grown on solid medium
overnight at 37°C prior to inoculating BHI broth (10 ml) with 109 bacteria. Cultures were grown to mid-log
phase (A600, 0.5) at 30°C, 37°C, or 42°C. Bacteria were collected by centrifugation (14,000  g for 5 min
at room temperature) and then resuspended in 100 l sample buffer prior to analysis by Western
blotting. Relative expression values were calculated by measuring band intensities with ImageJ software;
normalized to the signal for RecA, the loading control; and shown as a ratio relative to bacteria grown
at 30°C.
Surface plasmon resonance and ELISA. SPR was performed using a BiaCore 3000 instrument (GE
Healthcare). The purified proteins were immobilized on a CM5 sensor chip to approximately 800 reaction
units (RU) by amine coupling (GE Healthcare). Unreacted groups on the chip were inactivated with
ethanolamine. HSB-EB (HBS buffer; 0.01 M HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4) was used
throughout. Increasing concentrations of CFH6 –7, prepared as described previously (82) (0.5 nM to
32 nM), were injected over the chip at a flow rate of 40 l/min using the KINJECT command with a
dissociation time of 300 s. KD values were calculated and analyzed with BIAevaluation software. Kinetic
data were referenced against both a blank cell and subtraction of a blank injection (HSB-EB).
To determine CFH binding by ELISA, 96-well plates (F96 MaxiSorp; Nunc) were coated with recom-
binant fHbp (3 g/ml; 50 l per well) overnight at room temperature prior to blocking with 3% bovine
serum albumin (BSA) in PBS with 0.05% Tween 20. The plates were incubated with full-length human CFH
(Sigma) in 2-fold dilutions from 10 g/ml, and binding was detected with anti-CFH antibody (Millipore)
and HRP-conjugated goat anti-mouse polyclonal antibody (Dako). CFH binding was visualized with
3,3=,5,5=-tetramethylbenzidine (TMB) substrate reagent (Roche) and 2 N sulfuric acid stop solution
(Roche) according to the manufacturer’s instructions, and the A450 was measured (SpectraMax M5;
Molecular Devices). Statistical significance was tested using an unpaired Student t test (GraphPad Prism
v.6.0) to compare means and standard deviations (SD), with a P value of 0.05 as the cutoff for
significance. To analyze the reactivity of sera from mice immunized with Bexsero, ELISA plates were
coated with V1.1 fHbp, V1.110 fHbp, or BSA (2.5 g/ml; 50 l per well) prior to incubation with sera;
antibody binding was detected as described above. Pooled mouse sera were used as a primary antibody
with 3-fold dilutions from a starting dilution of 1:300.
Generation of N. cinerea fhbp mutants and complemented strains. N. cinerea strain CCUG 346TΔfhbp
was constructed by insertional inactivation of the fhbp gene with a cassette encoding kanamycin
resistance. NcΔfhbp (forward primer; 5=-GCCATATGGCTGAAAGTCATCAACGAAT-3= [NdeI site underlined])
and NcΔfhbp (reverse primer; 5=-GCCTCGAGGTGCAATACAAAATGCCGTCCGAACGGTAA-3= [XhoI site un-
derlined]) were used to amplify fhbp and flanking sequences from N. meningitidis strain H44/76Δfhbp.
The flanking sequences between N. meningitidis H44/76 and N. cinerea CCUG 346T shared 99.28% nucleic
acid sequence identity. N. cinerea CCUG 346 T was then transformed with a linear PCR fragment as
described previously (83). The complemented N. cinerea and N. meningitidis strains CCUG 346TΔfhbp::
fhbp and H44/76Δfhbp::V1.110 were constructed by amplifying fhbp from N. cinerea genomic DNA using
primers Nc fhbp forward (5=-CGGTTAATTAAGGAGTAATTTTTGTGAACC-3=; PacI site underlined) and Nc
fhbp reverse (5=-CGGTTAATTAATTATTGCTTGGCGGC-3=; PacI site underlined). The PCR products were
ligated into pNCC1 for transformation into N. cinerea (43) or PGCC4 for transformation into N. meningitidis
(84), which were linearized by ClaI digestion before transforming into N. cinerea or N. meningitidis as
described previously (83).
Flow cytometry. N. meningitidis and N. cinerea were grown on solid medium overnight and quantified
as described above. The bacteria (109 CFU) were fixed in 3% paraformaldehyde for 2 h at room
temperature and then washed with PBS. fHbp was detected using anti-V1.1 fHbp serum and goat
anti-mouse IgG Alexa Fluor 647-conjugated polyclonal antibody (Molecular Probes, Life Technologies). To
evaluate CFH binding, 5  107 CFU was resuspended in 20 l of HI-NHS or CFH-depleted serum
(CompTech, USA) for 30 min at room temperature. Binding of CFH was detected with an anti-CFH MAb
(OX24) and goat anti-mouse IgG Alexa Fluor 647-conjugated polyclonal antibody (Molecular Probes, Life
Technologies) (47). Samples were analyzed using a FACSCalibur (BD Biosciences), and at least 104 events
were recorded; the results were analyzed by calculating the geometric mean fluorescence intensity in
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FlowJo vX software (Tree Star). Statistical significance was tested using an unpaired Student t test
(GraphPad Prism v.6.0).
Serum sensitivity assays. NHS was obtained by collecting venous blood and allowing it to
coagulate at room temperature for 60 min before centrifuging it at 3,000  g for 20 min at 4°C prior to
storage at 80°C. The NHS was heat inactivated (HI-NHS) at 56°C for 30 min to inactivate complement.
N. cinerea and N. meningitidis were grown overnight on BHI agar, and then 104 CFU was incubated in
dilutions of NHS in PBS (0 to 20% [vol/vol] for N. cinerea; 0 to 75% [vol/vol] for N. meningitidis) for 30 min
at 37°C in the presence of CO2. To analyze the effect of the AP on bacterial survival, NHS was
preincubated with 5 mM MgCl2-10 mM EGTA to inhibit the classical and lectin pathways (48). Bacterial
survival was determined by plating onto BHI agar in triplicate. The percent survival was calculated by
comparing bacterial recovery in serum with recovery from samples containing no serum. Statistical
significance was tested using an unpaired Student t test or one-way ANOVA (GraphPad Prism v.6.0).
Generation of immune sera and SBA. Eight female BALB/c mice (6 to 8 weeks old; Charles River,
Margate, UK) were immunized with recombinant fHbp (20 g) adsorbed to aluminum hydroxide [final
composition, 0.5 mg/ml Al(OH)3, 10 mM histidine-HCl] by mixing overnight at 4°C or with Bexsero (total
protein, 20 g). Antigens were given by the intraperitoneal route on days 0, 21, and 35, and sera were
collected on day 49 by terminal anesthesia and cardiac puncture. All animal experiments were carried out
under protocols reviewed and approved by the Home Office, United Kingdom, under license number PPL
30/3194.
To measure SBA, N. cinerea was grown overnight on BHI agar prior to replating onto solid medium
and was grown for a further 5 h at 37°C in 5% CO2. A total of 5  104 CFU/ml of N. cinerea was mixed
with an equal volume of baby rabbit complement (Cedarlane) diluted 1:10 in SBA buffer (Dulbecco’s PBS
containing 0.1% [wt/vol] glucose, 1 mM CaCl2, 0.5 mM MgCl2). Sera from individual mice were pooled and
heat inactivated for 1 h at 56°C prior to being added to wells in 2-fold dilutions starting at 1:8. Control
wells contained either no serum or no complement. Following incubation for 1 h at 37°C, 10 l from each
well was plated onto BHI agar in triplicate, and the number of surviving bacteria was determined after
overnight growth. The SBA was expressed as the reciprocal of the highest dilution of serum required to
kill more than 50% of the bacteria relative to a no-serum control (49).
Statistical analysis. Statistical significance was calculated, using GraphPad Prism v.6.0, by unpaired
Student t test or one-way ANOVA as indicated. A P value of 0.05 was considered statistically significant.
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